Drain NP, Gobao VC, Bertolini DM, et al. - This study was attempted to distinguish if tranexamic acid (TXA) is correlated with decreased rate of periprosthetic joint infection (PJI), decreased rate of outcomes correlated with PJI, and if there are differences in rates of adverse events. Researchers designed a multicenter cohort study consisting 23,421 total knee arthroplasty (TKA) compared 4,423 individuals receiving TXA to 18,998 individuals not receiving TXA. PJI within 2 years of TKA was the primary endpoint. Revision surgery, irrigation and debridement, transfusion, and length of stay were considered as secondary endpoints. They identified adjusted odds ratios utilizing linear mixed models controlling for age, gender, thromboembolic prophylaxis, Charlson comorbidity index, year of TKA, and surgeon. The results showed that administration of TXA in TKA resulted in lowered rate of PJI and overall revision surgery. There were no difference in thromboembolic events. The use of TXA was found to be a safe and improves results in TKA.